Efficacy of apatinib mesylate combined with S-1 capsule in the treatment of stage III-IV esophageal cancer patients and its influence on quality of life
Objective To investigate the efficacy of apatinib mesylate combined with S-1 capsule in the treatment of stage III-IV esophageal cancer(EC)patients and its influence on quality of life.Method A total of 101 patients with stage III-IV EC were divided into observation group(50 cases)and control group(51 cases)according to different treat-ment methods.The observation group was treated with apatinib mesylate combined with S-1 capsule,and the control group was treated with S-1 capsule.The clinical efficacy,serum factor levels,incidence of adverse reactions and quality of life of the two groups were compared.Result The disease control rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After 3 cycles of treatment,the levels of vascular endo-thelial growth factor receptor 2(VEGFR2),vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)were decreased in both groups,and the levels of VEGFR2,VEGF and bFGF in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There were no significant differenc-es in the incidences of various adverse reactions between the two groups(P>0.05).After 3 cycles of treatment,the func-tional assessment of cancer therapy-general(FACT-G)scores of both groups were decreased,and the FACT-G score of ob-servation group was lower than that of control group,the differences were statistically significant(P<0.05).Conclusion Apatinib mesylate combined with S-1 capsule has obvious effect on patients with stage III-IV EC,which can regulate the levels of serum factors and improve the quality of life.
esophageal cancerS-1apatinib mesylatequality of life
NETL
NSTL
万方数据
